Sheldon Sloan - Oct 1, 2024 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Role
Chief Medical Officer
Signature
/s/ Heidy King-Jones, as Attorney-in-Fact
Stock symbol
SYRE
Transactions as of
Oct 1, 2024
Transactions value $
$0
Form type
4
Date filed
10/1/2024, 06:34 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRE Stock Option (Right to Buy) Award $0 +400K $0.00 400K Oct 1, 2024 Common Stock 400K $27.46 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which will vest and become exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.